Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | BTK | Q06187 | 4/20 | 0.37 |
| ▸ | BCR | P11274 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16972818 | 0.80 | GABRG2 (0.47) | YTHDC1GABRG2GABRB3GABRA5CNR2 | |
| SCHEMBL18226621 | 0.77 | YTHDC1 (0.50) | YTHDC1GABRG2GABRB3GABRA5CNR2 | |
| SCHEMBL16972821 | 0.77 | GABRG2 (0.45) | YTHDC1GABRG2GABRB3GABRA5BRD4 | |
| SCHEMBL31309753 | 0.76 | MTOR (0.44) | YTHDC1GABRG2GABRB3GABRA5CNR2 | |
| SCHEMBL30332108 | 0.75 | YTHDC1 (0.60) | YTHDC1CNR2 | |
| SCHEMBL18226598 | 0.75 | GABRG2 (0.48) | YTHDC1GABRG2GABRB3GABRA5 | |
| SCHEMBL26105431 | 0.72 | ADORA2A (0.46) | YTHDC1GABRG2GABRB3GABRA5 | |
| SCHEMBL2911823 | 0.72 | HSP90AA1 (0.51) | YTHDC1HSP90AA1HSP90AB1 | |
| SCHEMBL30612240 | 0.72 | ADORA2A (0.46) | YTHDC1GABRG2GABRB3GABRA5 | |
| SCHEMBL18226830 | 0.72 | GABRG2 (0.41) | YTHDC1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-10016439-B2 | Fused imidazole compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-3099672-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| WO-2015115673-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | YTHDC1 4478/4885GABRG2 14/4885GABRB3 10/4885 |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | YTHDC1 4478/4885GABRG2 14/4885GABRB3 10/4885 |
| US-10016439-B2 | Fused imidazole compounds | GABRA5, CHRNA5, GABRP | YTHDC1 4478/4885GABRG2 14/4885GABRB3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.